Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
Researchers discovered a molecular mechanism that makes glioblastoma resistant to mTOR inhibitors, leading to the development of a new treatment approach. The novel combination therapy combines an mTOR inhibitor with low-dose arsenic to reverse resistance and induce tumor cell death.
Moffitt researchers found that silencing the retinoblastoma gene can regulate the differentiation of myeloid-derived suppressor cells into a more aggressive form. This discovery may lead to new therapeutic strategies targeting these cells in cancer treatment.
Researchers at Scripps Research Institute have identified a mechanism controlling tumor aggressiveness and developed a simple treatment that inhibits cancer progression. In mice, the treatment prolongs life when tested with drugs already used for other conditions.
Researchers found that IQGAP1, a molecule controlling cell shape and movement, can suppress the growth of liver tumors when active in surrounding cells. The study provides new insight into cancer metastasis and points to potential therapeutic targets for preventing or treating liver metastases.
Scientists have identified a molecule called Gfi1 that represents the disease's Achilles' heel and could be targeted to develop a new approach. This discovery has direct implications for the treatment of acute lymphoblastic leukemia, a cancer of the bone marrow and blood that progresses rapidly.
A recent study published in Cell Reports found that sunitinib, an anticancer drug, does not cause lingering risks for patients after their treatment ends. The research suggests that sunitinib works by slowing tumor growth and prolonging survival during treatment, without altering tumor biology after the drug is stopped.
Researchers at Stanford University School of Medicine have discovered an antibody that can inhibit the growth of gastrointestinal stromal tumor (GIST) cells resistant to other treatments. The antibody targets KIT receptor mutations, stimulating immune cells to kill rogue cells.
A recent study found that the epigenetic marker 5-hydroxymethylcytosine (5hmC) plays a vital role in the selective expression of genes, particularly in healthy brain cells. The study also discovered that changes in 5hmC distribution are associated with gene silencing and may contribute to cancer development.
Biologists at Tufts University have identified a unique bioelectric signal in cells that are likely to develop into tumors, which they can use to detect early cancer. By manipulating the electrical charge across cells' membranes, they can lower the incidence of cancerous cells and suppress abnormal cell growth.
Researchers at UT MD Anderson Cancer Center found that tumor endothelial cells can trigger changes in cancer cells, making them more resistant to chemotherapy and more likely to spread. This signaling process involves the activation of the Notch molecular pathway and may be targeted by existing drugs under development.
Researchers found a subset of leukemia cells with slower metabolism, allowing them to survive better. An experimental drug tailored to this unique status is being tested for its ability to attack the disease.
Researchers found that cancer cells use unfolded protein response (UPR) to manipulate immune cells, making them ineffective against tumors. Tumor cells exploit UPR to promote their survival and growth, and this mechanism is being targeted for potential therapy and improved cancer vaccines.
Scientists have developed a new device that captures and preserves cancer cells circulating in the bloodstream, allowing for non-invasive diagnosis and insight into cancer spread. The technology could enable doctors to detect tumor cells earlier and provide valuable information on how cancer spreads throughout the body.
A team of researchers has discovered that the cellular reprogramming gene SOX2 is directly regulated by the tumor suppressor CDKN1B(p27) gene, which is also associated with cancers such as lung and pituitary cancer. The study also highlights the potential role of adult stem cells in cancer.
Researchers at University of California, San Diego School of Medicine discovered the reversible EMT switch in metastasis, resolving a decade-long debate. Activation of Twist1 gene promotes carcinoma cells to disseminate into blood circulation, while turning off EMT switch is crucial for proliferation and formation of secondary tumors.
A study published in Cancer Discovery reveals that microRNAs can modify gene expression, converting normal fibroblasts into cancer-associated fibroblasts that promote tumor growth. The researchers identified three microRNAs involved in this process and found that inhibiting these signals could disrupt the cancer's support system.
Researchers have created a new stem-like state of adult epithelial cells, which exhibit attributes favoring regenerative medicine. These cells do not express genes found in embryonic stem cells and induced pluripotent stem cells, making them stable and less prone to forming tumors.
A new gene delivery vehicle has been developed to target tumor cells with the TNFα cytokine, allowing for improved drug delivery and reduced resistance. The treatment approach combines the cytokine with a DNA-intercalating drug doxorubicin, showing promise in reducing tumor growth and metastasis.
A team of researchers found that tumour cells form alliances with surrounding healthy cells, called stroma, to colonize other organs during metastasis. This discovery could lead to a test to predict relapse and tailored treatment regimes for patients.
Resveratrol, a compound found in grape skins and red wine, has been shown to increase the susceptibility of prostate tumor cells to radiation treatment, leading to higher mortality rates. This discovery offers new hope for developing effective treatments for all types of prostate cancer, including aggressive tumors.
Researchers found that nisin slows or stops tumor growth by interrupting the cell cycle in cancer cells but not healthy ones. The study's findings suggest that nisin triggers cell death through the activation of protein CHAC1, which is a new role for this protein.
Researchers have identified a novel type of T cell that can selectively target and destroy melanoma tumors. The discovery involves combining cyclophosphamide, an antibody that activates OX40 on T cells, with adoptive T cell transfer to eradicate advanced melanoma tumors in mice.
Researchers discover that breast cancer cells' ability to spread is influenced by the tumor's protein-rich environment as much as genetic changes within the cells. The study reveals that a specific molecular signal in the protein meshwork can initiate metastasis to distant sites, while a healthy environment can even coax healthy cells ...
Researchers at the University of Minnesota have developed a new drug called Minnelide to target and destroy tumor cells in pancreatic cancer. The drug works by inhibiting heat shock protein HSP 70, which aids tumor cell growth, effectively disintegrating the cancer.
Researchers discovered that interleukin-36 may be a useful therapeutic target in the treatment of psoriasis, finding that mice lacking this protein were protected from immune-mediated skin inflammation. Additionally, studies on hypertension revealed that endoplasmic reticulum stress in brain cells contributes to high blood pressure, an...
Melanoma cells can temporarily alter their external characteristics to become invisible to defense cells, allowing them to evade destruction. This knowledge forms an important foundation for improving combination therapies and may also be relevant to treatment with inhibitors of signal transmission in tumor cells.
A new MIT study reveals cellular adhesion molecules critical to cancer's metastasis, offering potential new targets for cancer drug therapy. The researchers found that adhesion tendencies of metastatic cells from different primary tumors were similar, suggesting a shared pathway.
Researchers identified a group of proteins that play a key role in methylation, a process that silences genes in embryonic development. This phenomenon can be accidentally reactivated in tumor cells, leading to the formation of cancer.
Researchers have found that elevated expression of c-Myc amplifies the activity of all expressed genes in tumor cells, leading to increased transcription and proliferation. This discovery provides a simple explanation for how a single protein can have a profound effect in many types of cancer.
Researchers used a new cell technology to treat a patient with a rare type of lung tumor. The treatment, which uses conditionally reprogrammed cells, showed promising results, including some tumor shrinkage and stabilization of tumors after just three months.
Researchers identify a subpopulation of cancer stem cells that display resistance to chemotherapy and contribute to tumor progression. The study suggests a new therapeutic strategy by targeting these cancer stem cells with a combination of standard chemotherapy and signaling pathway inhibitors.
Ovarian cancer cells activate the HOXA9 gene to create an environment that supports tumor growth. Researchers also found blocking TGF-β expression in ovarian cancer cells significantly reduced tumor growth. Additionally, anti-CTLA therapy and inflammation-reversing treatments may hold promise for treating ovarian cancer and alcoholic l...
Researchers found that ovarian cancer cells hijack surrounding tissues by activating the HOXA9 gene, which induces TGF-β production and stimulates tumor growth. Blocking TGF-β expression reduced tumor growth, suggesting potential therapeutic targets for treating ovarian cancer.
Researchers discovered that FAM123A interacts with microtubule-associated proteins regulating cell movement. This interaction is crucial for normal development and life, as well as disease prevention.
The researchers successfully packaged siRNA in a hydrogel complex that can be injected into target tissues, allowing for prolonged control over cell behavior. The technology has the potential to guide stem cells to grow into desired cell types, starve tumors by blocking blood vessel growth, and induce cancer cell death.
Researchers have identified melanoma stem cells marked by the enzyme ALDH, which exhibit high tumorigenicity and resistance to chemotherapy. Targeting these cells with a new therapy could boost the effectiveness of existing drugs.
A UT Southwestern Medical Center study reveals that glioblastoma multiforme (GBM) recurs due to slower-growing 'cancer stem-like' cells. Researchers identified these cells as a potential target for future therapies, offering new hope for treatment.
A new study published in the FASEB Journal reveals that a molecule called 'flightless' significantly helps control cell movement through tissues. By increasing the stickiness of cells to underlying tissue, flightless slows their movement and may prevent cancer from spreading from one tissue to another.
Researchers identified 38 prognostic subnetworks of interacting genes that predict cancer progression in chronic lymphocytic leukemia. The study helps define how CLL evolves over time, becoming more aggressive and deadly.
Researchers discovered that tumor cells release chemokine CCL2, which docks onto endothelial cells and activates the CCR2 receptor, making them permeable. This pathway enables tumor cells to migrate and metastasize.
Researchers create high-throughput flow-through optical microscope to classify rare breast cancer cells in blood samples, boasting a throughput of 100,000 cells per second. The technology demonstrates real-time identification of rare cancer cells with a record low false-positive rate.
Researchers develop a new method to isolate and grow cancer cells, which can aid in understanding how cancer spreads and ultimately fighting it. The soft fibrin substrate promotes the growth of tumorigenic cells, making them more efficient at causing tumors.
Researchers showcased the breadth of zebrafish research at an international conference, focusing on cancer and nicotine dependence. A study found that mid-differentiated cells play a key role in tumor growth, challenging traditional views on cancer stem cells. Another study used zebrafish to identify novel candidate genes involved in n...
Researchers discovered that pancreatic cancer cells produce a protein that tricks the immune system into helping cancer growth. Blocking this protein may lead to effective treatments for pancreatic cancer. The findings suggest restoring the antitumor properties of a patient's immune system could be a therapeutic strategy.
Researchers at NYU School of Medicine have made a key discovery about the progression of pancreatic cancer, revealing how it escapes immune detection. By targeting a protein called GM-CSF, they found that immune cells can be unleashed to attack and halt tumor development.
A recent study found that targeting the JAK1 and JAK2 tyrosine kinase pathways can increase tumor cell susceptibility to natural killer cell-mediated death. Pharmacological inhibition of these pathways was shown to enhance tumor cell killing, making them a promising target for cancer therapy.
Researchers at IRB Barcelona have identified specific combinations of errors in cell integrity processes as crucial to initiating tumors. The study reveals that genomic instability alone is not sufficient for tumor development and highlights the need for further investigation into cancer's complex origins.
Researchers found that Skp2 E3 ligase promotes Herceptin resistance in breast cancer by activating the Akt kinase, which also regulates glucose metabolism. The study suggests that blocking Skp2 could inhibit glycolysis and provide a new approach to cancer treatment.
Scientists have identified the Mitochondrial Pyruvate Carrier (MPC), a universal carrier that transports pyruvate into mitochondria. This discovery could lead to a better understanding of how cancer cells produce energy and potentially develop new treatments.
Researchers at Massachusetts General Hospital identified a tumor-propagating cell required for growth in a pediatric muscle tumor model. Another type of differentiated tumor cell must first colonize new areas to prime an environment for metastatic growth.
Researchers identified a cell surface protein ganglioside GD2 that flags breast cancer stem cells as potent tumor-generating cells. A small molecule drug triptolide inhibits GD3 synthase, essential to GD2 production, and stymies cancer growth in preclinical tests.
Researchers have discovered that children's brain tumors preserve characteristics of the normal cells from which they originate, offering new hope for effective treatments. The study found that tumour malignancy is linked to cellular origin and time of tumour development, improving prospects for targeted therapies.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
A new Stanford study reveals that the cells sloughed off from a cancerous tumor into the bloodstream are genetically diverse and may require different treatments. The research found that these cells can express genes that predict their response to therapy, highlighting the need for personalized treatment approaches.
Researchers have identified a molecule, PDE4, that plays a key role in regulating the division of tumor cells and blood vessel growth in lung cancer. By blocking PDE4, they were able to significantly reduce tumor growth in laboratory experiments and mouse models.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
Researchers have discovered that the NKCC1 protein may hold key to understanding how glioblastoma, the deadliest type of brain cancer, moves and invades healthy brain tissue. Blocking NKCC1 with a cheap FDA-approved drug slows movement of glioblastoma cells, suggesting a potential new approach to treat this aggressive cancer.
Researchers have discovered that NKCC1 protein facilitates the movement of glioblastoma cells, which are notoriously aggressive and deadly. The study also suggests that a cheap FDA-approved drug, bumetanide, could slow cell migration and contain tumor spread.
Researcher Carlos Martino explores how fluctuations in static and radiofrequency magnetic fields impact biochemical reactions. His work shows that low-level fields can inhibit tumor growth and modulate cellular proliferation, offering potential for a therapy based on weak radiofrequency fields.
A recent study published in PNAS contradicts the prevailing belief that basal-like cells are responsible for invasive tumors. Luminal-like cells, previously thought to lack stem cell properties, have been found to be highly tumorigenic and capable of generating larger tumors than their basal-like counterparts.